Coronary bypass surgery after renal transplantation

• Published in: General thoracic and cardiovascular surgery Vol. 47; no. 3; pp. 135 - 140
• Main Authors: Noda, H, Fujimura, Y, Gohra, H, Hamano, K, Katoh, T, Esato, K
• Format: Journal Article
• Language: English
• Published: Japan Springer Nature B.V 01.03.1999
• Subjects: Adult; Azathioprine - administration & dosage; Cardiopulmonary Bypass - methods; Coronary Artery Bypass - methods; Coronary vessels; Cyclophosphamide - administration & dosage; Cyclosporine - administration & dosage; Heart surgery; Humans; Immunosuppressive Agents - administration & dosage; Kidney Transplantation; Kidney transplants; Male; Middle Aged; Patients
• ISSN: 1344-4964; 1863-6705; 1863-2092; 1863-6713
• DOI: 10.1007/BF03217958

We report, herein, cases of two renal transplantation patients who underwent coronary artery bypass grafting and discuss the perioperative management of this clinical situation. The first case was a 43-year-old male who underwent coronary artery bypass grafting 50 days after renal transplantation, and the second was a chronic case of a 49-year-old male who underwent coronary artery bypass grafting 17 years after renal transplantation. Prior to the operation, the first patient was continuously administered 2 mg/kg/day of cyclosporin A with the dosage regulated according to the plasma level. The second patient was administered 50 mg/day of cyclophosphamide intravenously instead of an oral dosage of 50 mg/day of azathioprine just prior to the operation. In both patients, perfusion pressure during cardiopulmonary bypass was maintained at approximately 80 mmHg in order to obtain optimal urine output. The CD4/CD8 ratio was monitored for indication of graft rejection, but no remarkable changes were observed perioperatively in either patient. Both patients followed a good clinical course and their postoperative renal function was well maintained. The urine output during cardiopulmonary bypass was 300 ml and 650 ml, respectively. The patients were discharged 15 and 27 days after their operation, respectively. In conclusion, coronary artery bypass grafting can be safely performed in patients who have undergone renal transplantation, if there is appropriate perioperative usage of immunosuppressive agents and maintenance of perfusion pressure during cardiopulmonary bypass.